GENITOURINARY CANCERS

Rucaparib (Rubraca) has received a breakthrough therapy designation from the FDA&nbsp;for single-agent use in adult patients with <em>BRCA1/2</em>-positive metastatic castration-resistant prostate cancer following at least 1 androgen receptor&ndash;directed therapy and taxane-based chemotherapy.

Patients with the localized form of CRPC still have no options that are proven to extend overall survival, but preliminary results from the PROSPER trial of enzalutamide and the SPARTAN trial of apalutamide offer them unprecedented hope.

The FDA has received a new drug application for&nbsp;erdafitinib as a treatment for&nbsp;patients with locally advanced or metastatic urothelial carcinoma and <em>FGFR</em> genetic alterations whose tumors progressed following chemotherapy,&nbsp;Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor, has announced.

Padmanee Sharma, MD, PhD,&nbsp;shares insight on the current state of immunotherapy in the treatment of patients with GU cancers.

Susan Halabi, PhD, discusses an analysis that found&nbsp;that the risk of death from&nbsp;metastatic castration-resistant prostate cancer was nearly 20% lower in African-American men than in Caucasian men.

Olaparib in combination with abiraterone acetate improved progression-free survival compared with the antiandrogen agent alone in patients with metastatic castration-resistant prostate cancer, according to findings from a phase II trial presented at the 2018 ASCO Annual Meeting.&nbsp;The results of the trial were also published the same day in Lancet Oncology.

Sumanta Kumar Pal, MD,&nbsp;sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

According to Pfizer and Astellas, the codevelopers of&nbsp;enzalutamide (Xtandi), the agent has been approved by the FDA for treatment of patients with nonmetastatic castration-resistant prostate cancer.

Sunitinib alone was noninferior for median overall survival compared with sunitinib plus cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma, according to findings from the phase III noninferiority CARMENA trial.

General Cancer

Brian I. Rini, MD,&nbsp;discusses atezolizumab and bevacizumab as an effective frontline combination in RCC, as well as PROs with the regimen.&nbsp;

Joseph F. Renzulli Jr, MD, an expert in robotic surgery for treating urologic cancers, is joining Lawrence and Memorial Hospital, an affiliate of Yale New Haven Health, in New London, Connecticut. He brings a specialized insight on diagnosing and treating prostate cancer to the growing team.

Newer MRI techniques are being tested to improve the accuracy of prostate cancer diagnosis. Three presentations during the 2018 American Urological Association Annual Meeting discussed potential approaches to reduce the need for prostate biopsies for men with prostate cancer

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.